Epidemiological and genetic factors associated with ovarian cancer

Cancer Nursing

Volumn 32, Issue 4, 2009, Pages 281-288

  McLemore, Monica R ^a   Miaskowski, Christine ^a   Aouizerat, Bradley E ^a   Chen, Lee May ^a   Dodd, Marylin J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Early detection; Epidemiology; Genetics; Ovarian cancer; Risk factors; Screening

Indexed keywords

ACETYLSALICYLIC ACID; ASBESTOS; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; CLOMIFENE; ESTROGEN; ETHINYLESTRADIOL PLUS NORELGESTROMIN; HUMAN MENOPAUSAL GONADOTROPIN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NUVA RING; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; TALC; UNCLASSIFIED DRUG; UROFOLLITROPIN;

BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME 13Q; CHROMOSOME 17Q; CIGARETTE SMOKING; COLORECTAL CANCER; DIETARY INTAKE; DISEASE ASSOCIATION; EARLY DIAGNOSIS; ETHNICITY; FAMILIAL CANCER; FAMILY HISTORY; FEMALE INFERTILITY; GENE LOCATION; GENETIC RISK; HEREDITY; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; INFERTILITY; INFORMATION DISSEMINATION; NURSE ATTITUDE; NURSING ASSESSMENT; OBESITY; OVARY CANCER; OVARY HYPERSTIMULATION; PARITY; PATIENT INFORMATION; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF NURSING CARE; REVIEW; RISK ASSESSMENT; RISK FACTOR; STOP CODON; TRANSVAGINAL ECHOGRAPHY;

ABDOMINAL PAIN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CA-125 ANTIGEN; DIET; EARLY DETECTION OF CANCER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MASS SCREENING; OBESITY; ONCOLOGIC NURSING; OVARIAN NEOPLASMS; PEDIGREE; PELVIC PAIN; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; URINATION DISORDERS;

EID: 67651123146     PISSN: 0162220X     EISSN: None     Source Type: Journal    
DOI: 10.1097/NCC.0b013e31819d30d6     Document Type: Review

References (65)

1. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J, eds. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program: Bethesda, MD; 2007. NIH Publication No. 07-6215.
2. National Cancer Institute (NCI). http://dcp.cancer.gov/programs- resources/ groups/ed/programs/plco/about. Accessed November 3, 2008.
3. Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, and the PLCO Project Team. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol. 2005;193(5): 1630-1639. (Pubitemid 41540458)
4. Pauler DK, Menon U, McIntosh M, Symecko HL, Skates SJ, Jacobs IJ. Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2001;10:489-493. (Pubitemid 32701635)
5. Gynecologic Cancer Foundation (2008). http://www.wnc.org/ov-cancer-cons. html. Accessed August 25, 2008.
6. Twombly R. Cancer killer may be "silent" no more. J Natl Cancer Inst. 2007;99(18):1359-1361.
7. Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007; 109(2):221-227. (Pubitemid 46106236)
8. Andersen MR, Goff BA, Lowe KA, et al. Combining a symptoms index with CA125 to improve detection of ovarian cancer. Cancer. 2008;113: 484-489.
9. Modugno F, and the Ovarian Cancer and High-Risk Women Symposium Presenters. Ovarian cancer and high-risk women Vimplications for prevention, screening and early detection. Gynecol Oncol. 2003;91:15-31.
10. Coukos G, Rubin SC. Prophylactic oophorectomy. Best Pract Res Clin Obstet Gynecol. 2002;16(4):597-609.
11. Agnantis NJ, Paraskevaidis E, Roukos D. Editorial: preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol. 2004;11(12):1030-1034. (Pubitemid 40486647)
12. Dowdy SC, Stefanek M, Hartmann LC. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy. Am J Obstet Gynecol. 2004;191:1113-1123. (Pubitemid 39421559)
13. Rubin SC, Sutton GP. Ovarian Cancer. 2nd ed. Philadelphia, PA: Lippincott, Williams, & Wilkins; 2004:170, 195-197.
14. Villella JA, Parmar M, Donohue K, Fahey C, Piver MS, Rodabaugh K. Role of prophylactic hysterectomy in patients at high risk for hereditary cancers. Gynecol Oncol. 2006;102(3):475-479. (Pubitemid 44353643)
15. Riman T, Dickman PW, Nilsson S, Nordlinder H, Magnusson CM, Persson IR. Some life-style factors and the risk of invasive epithelial ovarian cancer in Swedish women. Eur J Epidemiol. 2004;19:1011-1019. (Pubitemid 40142802)
16. Pike MC, Pearce CL, Peters R, Cozen W, Wan P, Wu AH. Hormonal factors and the risk of invasive ovarian cancer: a population-based casecontrol study. Fertil Steril. 2004;82(1):186-195. (Pubitemid 38968797)
17. Ho SM. Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol. 2003;1:73-81.
18. Whittemore AS, Harris R, Itnyre J, The Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies: invasive epithelial ovarian cancers in white women. Am J Epidemiol. 1992;136(10):1184-1203. (Pubitemid 23026890)
19. John EM, Whittemore AS, Harris R, Intyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of seven US case-control studies: epithelial ovarian cancer in black women. J Natl Cancer Inst. 1993; 85(2):142-146. (Pubitemid 23028718)
20. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst. 1983;71(4):717-721. (Pubitemid 14232385)
21. Elit L, Esplen MJ, Butler K, Narod S. Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer. Fam Cancer. 2001;1(3Y4):149-156. (Pubitemid 35407936)
22. Russo A, Calo V, Bruno L, Rizzon S, Bazan V, Di Fede G. Hereditary ovarian cancer. Crit Rev Oncol Hematol. 2009;69(1):28-44. (Epub July 24, 2008. Review.)
23. Lu KH. Hereditary gynecologic cancers: differential diagnosis, surveillance, management, and surgical prophylaxis. Fam Cancer. 2008;7(1):53-58.
24. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999;91(17):1459-1467. (Pubitemid 29424550)
25. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL, Shore RE. Aspirin and epithelial ovarian cancer. Prev Med. 2001; 33(6):682-687.
26. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991;325:1593-1596.
27. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER. Over the counter analgesics and the risk of ovarian cancer. Lancet. 1998;351:104-107. (Pubitemid 28026637)
28. Rosenberg L, Palmer JR, Rao RS, et al. A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2000;9(9): 933-937. (Pubitemid 30743516)
29. LaVecchia C, Decarli A, Negri E, et al. Dietary factors and the risk of epithelial ovarian cancer. J Natl Cancer Inst. 1987;79(4):663-669. (Pubitemid 17146828)
30. Kushi LH, Mink PJ, Folson AR, et al. Prospective study of diet and ovarian cancer. Am J Epidemiol. 1999;149(1):21-31. (Pubitemid 29028858)
31. Larsson SC, Bergkvist L, Wolk A. Milk and lactose intakes and ovarian cancer risk in the Swedish mammography cohort. Am J Clin Nutr. 2004; 80:1353-1357.
32. Larsson SC, Holmberg L, Wolk A. Fruit and vegetable consumption in relation to ovarian cancer incidence: the Swedish mammography cohort. Br J Cancer. 2004;90:2167-2170. (Pubitemid 38869724)
33. McCann SE, Fredudenheim JL, Marshall JR, Graham S. Risk of human ovarian cancer is related to dietary intake of selected nutrients, phytochemical and food groups. J Nutr Epidemiol. 2003;133:1937-1942. (Pubitemid 36666538)
34. Goodman MT, Wu AH, Tung KH, et al. Association of dairy products, lactose, and calcium with the risk of ovarian cancer. Am J Epidemiol. 2002;156(2):148-157. (Pubitemid 34755953)
35. Salazar-Martinez E, Lazcano-Ponce EC, Lira-Lira GG, Escudero-de los Rios P, Hernandez-Avila M. Nutritional determinants of epithelial ovarian cancer risk: a case-control study in Mexico. Oncology. 2002;63: 151-157.
36. Schouten LJ, Zeegers MA, Goldbohm A, vanden Brandt PA. Alcohol and ovarian cancer risk: results from the Netherlands cohort study. Cancer Causes Control. 2004;15:201-209.
37. Lagiou P, Ye W, Wedren S, et al. Incidence of ovarian cancer among alcoholic women: a cohort study in Sweden. Int J Cancer. 2001;91(2): 264-266. (Pubitemid 32041751)
38. Kuper H, Titus EL, Harlow BL, Cramer DW. Population based study of coffee, alcohol, and tobacco use and risk of ovarian cancer. Int J Cancer. 2000;88:313-318. (Pubitemid 30745229)
39. Gwinn ML, Webster LA, Lee NC, Layde PM, Rubin GL. Alcohol consumption and ovarian cancer risk. Am J Epidemiol. 1986;123:759-766. (Pubitemid 16049232)
40. Women's Health Initiative (WHI) Web site. http://www.whi.org/findings. Accessed November 4, 2008.
41. Gambacciani M, Monteleone P, Sacco A, Genazzani AR. Hormone replacement therapy and endometrial, ovarian, and colorectal cancer. Best Pract Res Clin Endocrinol Metab. 2003;17(1):139-147. (Pubitemid 36372152)
42. Green A, Purdie D, Bain C, et al. Tubal sterilization, hysterectomy, and decreased risk of ovarian cancer. Int J Cancer. 1998;71(6):948-951. (Pubitemid 27252873)
43. Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk after use of ovulation-stimulation drugs. Obstet Gynecol. 2004;103(6):1194-1203. (Pubitemid 40458949)
44. Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Andersen AN. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril. 1997;67(6):1005-1012. (Pubitemid 27241890)
45. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. N Engl J Med. 1994;331:771-776.
46. Venn A, Watson L, Lumley J, Giles G, King C, Healy D. Breast and ovarian cancer incidence after infertility and in-vitro fertilisation. Lancet. 1995;346:995-1000.
47. Shushan A, Paltiel O, Iscovich J, Elchalal U, Pertz T, Schenker JG. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril. 1996;65:13-18. (Pubitemid 26006641)
48. Farrow DC, Weiss NS, Lyon JL, Daring JR. Association of obesity and ovarian cancer in a case-control study. Am J Epidemiol. 1989;129(6): 1300-1304. (Pubitemid 19148470)
49. Rodriguez C, Calle EE, Fakhrabadi-Shokoohi D, Jacobs EJ, Thun MJ. Body mass index, height, and the risk of ovarian cancer mortality in a prospective cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2002;11:822-828. (Pubitemid 35014884)
50. Dibble SL, Roberts SA, Robertson PA, Paul SM. Risk factors for ovarian cancer: lesbian and heterosexual women. Oncol Nurs Forum. 2002;29(1): E1-E7.
51. Runnebaum IB, Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol. 2001;127:73-79. (Pubitemid 32128518)
52. National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/ guidelines/obesity/practgde.htm. Accessed January 13, 2008.
53. Marchbanks PA, Wilson H, Bastos E, Cramer D, Schildkraut JM, Peterson HB. Cigarette smoking and epithelial ovarian cancer by histologic type. Obstet Gynecol. 2000;95:255-260. (Pubitemid 30045650)
54. Whittemore AS, Wu ML, Paffenbarger RS, et al. Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol and coffee. Am J Epidemiol. 1988;128(6): 1228-1240. (Pubitemid 19015496)
55. Modugno F, Ness RB, Cottreau CM. Cigarette smoking and the risk of mucinous and non-mucinous epithelial ovarian cancer. Epidemiology. 2002;13:467-471. (Pubitemid 34627847)
56. Goodman MT, Tung KH. Active and passive tobacco smoking and the risk of borderline and invasive ovarian cancer (United States). Cancer Causes Control. 2003;14:569-577.
57. Terry PD, Miller AB, Jones JG, Rohan TE. Cigarette smoking and the risk of invasive epithelial ovarian cancer in a prospective cohort study. Eur J Cancer. 2003;39:1157-1164.
58. Pan SY, Ugnat AM, Mao Y, Wen SW, Johnson KC, The Canadian Cancer Registries Epidemiology Research Group. Association of cigarette smoking with the risk of ovarian cancer. Int J Cancer. 2004;111: 124-130.
59. Green A, Purdie D, Bain C, Siskind V, Webb PM. Cigarette smoking and risk of epithelial ovarian cancer (Australia). Cancer Causes Control. 2001;12:713-719. (Pubitemid 32803498)
60. Graham J, Graham R. Ovarian cancer and asbestos. Environ Res. 1967; 2:115-128.
61. Huncharek M, Geschwind JF, Kupelnick B. Perineal application of cosmetic talc and risk of invasive epithelial ovarian cancer: a meta-analysis of 11, 933 subjects from sixteen observational studies. Anticancer Res. 2003; 23:1955-1960. (Pubitemid 36750874)
62. Mills PK, Riordan DG, Cress RD, Young HA. Perineal talc exposure and epithelial ovarian cancer risk in the central valley of California. Int J Cancer. 2004;112:458-464. (Pubitemid 39390611)
63. Harlow BL, Cramer DW, Bell DA, Welch WR. Perineal exposure to talc and ovarian cancer risk. Obstet Gynecol. 1992;80(1):19-26.
64. Tzonou A, Polychronopoulou A, Hsieh C, Rebelakos A, Karakatsami A, Trichopoulos D. Hair dyes, analgesics, tranquilizers, and perineal talc application as risk factors for ovarian cancer. Int J Cancer. 1993;55:408-410. (Pubitemid 23300589)
65. World Health Organization Web site. http://www.who.int/cancer/resources/ incidences/en/. Accessed November 4, 2008.